ORLANDO, Fla. – The Food and Drug Administration approved the first coronavirus test that will be tested entirely at the point of care for a patient, according to a news release.
Cepheid, a molecular diagnostics company, announced Saturday that it has received Emergency Use Authorization from the U.S. Food and Drug Administration for Xpert Xpress SARS-CoV-2.
The rapid molecular diagnostic test is able to detect SARS-CoV-2, the virus causing COVID-19. According to Cepheid, the test is able to deliver results in 45 minutes. “During this time of increased demand for hospital services, Clinicians urgently need an on-demand diagnostic test for real-time management of patients being evaluated for admission to health-care facilities.